Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts
暂无分享,去创建一个
E M Lord | J. Frelinger | B. Fenton | S. Gerber | J. Frelinger | E. Lord | B M Fenton | S A Gerber | J P Moran | J G Frelinger | J A Frelinger | J. P. Moran | Bruce M. Fenton | Edith M. Lord | J. A. Frelinger | Scott A. Gerber
[1] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[2] S. Fuggle,et al. THE DETAILED DISTRIBUTION OF HLA‐A, B, C ANTIGENS IN NORMAL HUMAN ORGANS , 1984, Transplantation.
[3] J. Folkman,et al. Tumoral vascularity as a prognostic factor in cancer. , 1996, Important advances in oncology.
[4] G. Trinchieri,et al. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. , 1995, Cancer research.
[5] J. Folkman,et al. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.
[6] K. Alitalo,et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. , 1999, The American journal of pathology.
[7] M. Serio,et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. , 2001, The Journal of clinical investigation.
[8] M. Karkkainen,et al. Vascular endothelial growth factor receptor-3. , 1999, Current topics in microbiology and immunology.
[9] T. Veikkola,et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.
[10] E. Berg,et al. Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier , 1995, Developmental dynamics : an official publication of the American Association of Anatomists.
[11] P. Vaupel,et al. Hypoxia-stimulated expression of angiogenic growth factors in cervical cancer cells and cervical cancer-derived fibroblasts , 2001, International Journal of Gynecologic Cancer.
[12] B. Car,et al. The Toxicology of Interleukin-12: A Review , 1999, Toxicologic pathology.
[13] R. D'Amato,et al. Inhibition of angiogenesis in vivo by interleukin 12. , 1995, Journal of the National Cancer Institute.
[14] S. Stacker,et al. Localization of vascular endothelial growth factor‐D in malignant melanoma suggests a role in tumour angiogenesis , 2001, The Journal of pathology.
[15] M. Colombo,et al. IL-12 Inhibition of Endothelial Cell Functions and Angiogenesis Depends on Lymphocyte-Endothelial Cell Cross-Talk1 , 2001, The Journal of Immunology.
[16] G. Trinchieri,et al. Interleukin-12: basic principles and clinical applications. , 1999, Current topics in microbiology and immunology.
[17] P. Lollini,et al. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. , 1998, Cancer research.
[18] S. Pestka,et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. , 1998, Immunity.
[19] C. Orosz,et al. Inducible expression of an endothelial cell antigen on murine myocardial vasculature in association with interstitial cellular infiltration. , 1989, Transplantation.
[20] N. J. McNally,et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). , 1998, British Journal of Cancer.
[21] A. Chang,et al. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. , 1996, Cancer research.
[22] Stanley J. Wiegand,et al. Vascular-specific growth factors and blood vessel formation , 2000, Nature.
[23] D. Ruiter,et al. Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma. , 2002, Cancer research.
[24] K. Alitalo,et al. VEGF‐C and VEGF‐D expression in neuroendocrine cells and their receptor, VEGFR‐3, in fenestrated blood vessels in human tissues , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[25] G. Trinchieri,et al. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. , 1997, Cancer research.
[26] G. Trinchieri. Interleukin-12: a cytokine at the interface of inflammation and immunity. , 1998, Advances in immunology.
[27] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[28] T. Veikkola,et al. VEGFs, receptors and angiogenesis. , 1999, Seminars in cancer biology.
[29] N. Yang,et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[30] A. Angiolillo,et al. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. , 1996, Blood.
[31] K. Alitalo,et al. Vascular endothelial growth factor C induces angiogenesis in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[32] R. Tisch,et al. Distribution and characterization of GFP(+) donor hematogenous cells in Twitcher mice after bone marrow transplantation. , 2000, The American journal of pathology.
[33] K. Sullivan,et al. Green Fluorescent Proteins , 1999 .
[34] A. McAdam,et al. Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor. , 1995, Cellular immunology.
[35] P. Vaupel. Hypoxia in neoplastic tissue. , 1977, Microvascular research.
[36] J. Folkman. Tumor angiogenesis in women with node-positive breast cancer. , 1995, The cancer journal from Scientific American.
[37] L. Luistro,et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.
[38] P. Hewett,et al. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. , 2002, Cancer research.
[39] D. Brewster,et al. Trends in cancer incidence and mortality in Scotland: description and possible explanations. , 1998, British Journal of Cancer.
[40] F. Balkwill,et al. IL‐12 regulates VEGF and MMPs in a murine breast cancer model , 1998, International journal of cancer.